The direct answer: PB's Wharton's jelly products are not FDA approved
PB's products are not FDA approved or licensed for any disease or condition. Request the regulatory documentation for any specific product under consideration rather than relying on a marketing claim about approval status.
This is not necessarily unusual or disqualifying on its own. Tissue products in this category are generally regulated under a different framework than drugs or devices, one that does not involve a premarket approval process at all. Understanding which framework applies, and why, is more useful to a buyer than the yes-or-no question alone.
How these products are actually regulated
Wharton's jelly products are generally offered under the human cell and tissue product, or HCT/P, framework described in 21 CFR 1271.10. Qualification solely under section 361 of the Public Health Service Act, without FDA premarket approval, depends on all applicable criteria set out in that regulation, not on any single factor in isolation.
Whether a specific product and a specific intended use at a specific clinic meets the applicable criteria in 21 CFR 1271.10 is a determination made case by case. It depends on how the product is processed, how it is described in labeling and marketing, and how a clinic intends to use it. That determination belongs to the clinic and its own regulatory counsel, not to a supplier's marketing page.
Minimal manipulation and homologous use as applicable criteria
Minimal manipulation and homologous use are among the applicable criteria in 21 CFR 1271.10. Counsel should assess the full rule, including all criteria and exceptions, for the specific tissue, processing, and intended use in question.
FDA has stated plainly that intended use is not just a label question. The agency has said it looks at a distributor's website, marketing claims, and social media content as evidence of intended use. That means how a product is described publicly can affect its regulatory classification, independent of how it was processed.
Why 'stem cell' labeling is not supported for the products studied so far
Wharton's jelly is the gelatinous connective tissue of the umbilical cord, rich in hyaluronic acid, collagen, and growth factors. It is sometimes marketed using stem cell language, but two published studies cited here report more limited findings. A 2026 analysis of six commercial Wharton's jelly products found low total cell counts and low viability, with only rare viable mesenchymal stromal cells identified. A separate 2021 study found no colony-forming mesenchymal stromal cells across five commercial cord products tested.
Clinics searching for a stem cell supplier should know that PB's Wharton's jelly products are not stem cell therapies and are not marketed as such. The studies above describe the specific products tested and do not establish findings for every supplier's manufacturing process, so a clinic evaluating a particular product should request that supplier's own donor eligibility, processing, and testing documentation rather than extending findings about other products. Whether a product has a place in a given clinical workflow remains a decision for the treating physician.
What FDA enforcement history shows
FDA's compliance policy that allowed broader latitude for some HCT/P products ended May 31, 2021. Since then, the agency has issued warning letters to distributors over marketing content, not only manufacturing practices. In 2026, FDA sent a warning letter to a distributor of private-label Wharton's jelly and exosome products, citing disease-related claims made on company websites and social media.
This history is a useful reference point for any clinic evaluating a supplier, because FDA has been explicit that it treats distributor and affiliate marketing, not just a supplier's own internal statements, as evidence of a product's intended use.
What this means for purchasing and marketing decisions
For a clinic, the practical takeaway is to separate two questions: whether a product's processing and documentation fit the section 361 HCT/P framework for a specific intended use, and how the clinic itself describes the product in its own marketing and patient materials. Both matter, and both carry independent risk if handled carelessly.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice. A clinic making a section 361 intended-use determination, or evaluating its own marketing language, should do so with its own FDA regulatory counsel.
Frequently asked questions
Is any Wharton's jelly product FDA approved?+
PB's products are not FDA approved or licensed for any disease or condition. Request the regulatory documentation for any specific product you are evaluating, since suppliers can differ in what they offer and how they describe it.
What does '361 HCT/P' mean in practice?+
It refers to human cell and tissue products regulated solely under section 361 of the Public Health Service Act when they meet the applicable criteria in 21 CFR 1271.10, without requiring premarket approval. Meeting those criteria for a specific use is a case-by-case determination for the clinic and its counsel.
Can a clinic call these products stem cell therapy?+
No. Published studies of a sample of commercial cord-tissue products found low cell viability and little to no colony-forming mesenchymal stromal cell activity. That evidence does not support stem cell therapy language for the products studied, and a clinic should request a specific supplier's own documentation before using that language for any product.
Who decides whether a specific intended use qualifies under 21 CFR 1271.10?+
Whether a specific intended use meets all applicable criteria in 21 CFR 1271.10 is a determination for the clinic and its counsel. This article is educational and is not legal advice.
Sources
- 21 CFR 1271.10 - Are my HCT/Ps regulated solely under section 361 of the PHS Act ↗eCFR
- Warning letter: R3 Medical Companies (CBER 26-726330, Aug 14 2026) ↗FDA
- Umbilical cord-derived Wharton's jelly for regenerative medicine: a systematic review ↗PMC8618385
- Colony forming potential and protein composition of commercial umbilical cord allograft products ↗Am J Sports Med